Narrative review / 2000
High-dose nicotinamide is generally well tolerated, but reversible hepatotoxicity and toxic potential can occur at adult doses exceeding 3 g/day.
A literature review evaluated the safety of high-dose nicotinamide, which is being studied for preventing type 1 diabetes mellitus. Nicotinamide has a wide therapeutic index, but reversible hepatotoxicity has been reported at very high doses in animals and humans, with minor liver enzyme abnormalities infrequently occurring at diabetes-prevention doses. Growth was unaffected in children, and no evidence of oncogenicity was found in humans, though minor insulin resistance has been reported. The authors conclude that while the risk-to-benefit ratio appears favourable for diabetes prevention if efficacious, unsupervised use should be discouraged and doses above 3 g/day in adults carry toxic potential.
- Study type
- Literature review
- Who was studied
- Humans and animals across published studies
- What was measured
- Safety, hepatotoxicity, oncogenicity, teratogenicity, and metabolic effects
THE PAPER
Safety of high-dose nicotinamide: a review.
Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA, European Nicotinamide Diabetes Intervention Trial Group. Diabetologia, 2000.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.